Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer

European Journal of Cancer

Volumn 36, Issue 12, 2000, Pages 1498-1506

  Kramer, J A ^a   Curran, D ^a   Piccart, M ^b   De Haes, J C J M ^c   Bruning, P ^d   Klijn, J ^e   Van Hoorebeeck, I ^f   Paridaens, R ^g  

^a EORTC DATA CENTER   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f Investigational Drug Br Breast C   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; EORTC QLQ C30; Prognostic factor; Quality of life

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DYSPNEA; EMOTION; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELIABILITY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033861604     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00144-1     Document Type: Article

References (32)

1. Curran D., Sahmoud T., Therasse P., van Meerbeek J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma. the European Organization for Research and Treatment of Cancer experience J. Clin. Oncol. 16:1998;145-152.
2. Simon R., Altman D.G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer. 69:1994;979-985.
3. Coates A., Gebski V., Bishop J.F.et al. for the Australian-New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 317:1987;1490-1495.
4. Coates A., Gebski V., Signorini D.et al. for the Australian New Zealand Breast Cancer Trials Group. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J. Clin. Oncol. 10:1992;1833-1838.
5. Coates A., Thomson D., McLeod G.R.M.et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur. J. Cancer. 29A:1993;1731-1734.
6. Seidman A.D., Portenoy R., Yao T.-J.et al. Quality of life in phase II trials. a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor J. Natl. Cancer Inst. 87:1995;1316-1322.
7. Ganz P.A., Lee J.J., Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 67:1991;3131-3135.
8. Buccheri G.F., Ferrigno D., Tamburini M., Brunelli C. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. Lung Cancer. 12:1995;45-58.
9. Tamburini M., Brunelli C., Rosso S., Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J. Pain Symptom. Manage. 11:1996;32-41.
10. Earlam S., Glover C., Fordy C., Burke D., Allen-Mersh T.G. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J. Clin. Oncol. 14:1996;171-175.
11. De Boer M.F., Van den Borne B., Pruyn J.F.et al. Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma. results of a 6-year longitudinal study Cancer. 83:1998;2567-2579.
12. Loprinzi C.L., Laurie J.A., Wieand H.S.et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. J. Clin. Oncol. 12:1994;601-607.
13. Degner L.F., Sloan J.A. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J. Pain Symptom. Manage. 10:1995;423-431.
14. Aaronson N.K., Ahmedzai S., Bergman B.et al. The European Organization for Research and Treatment of Cancer QLQ-C30. a quality of life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85:1993;365-376.
15. Coates A., Porzsolt F., Osoba D. Quality of life in oncology practice. prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy Eur. J. Cancer. 33:1997;1025-1030.
16. Dancey J., Zee B., Osoba D.et al. for the National Cancer Institute of Canada Clinical Trials Group. Quality of life scores. an independent prognostic variable in a general population of cancer patients receiving chemotherapy Qual. Life Res. 6:1997;151-158.
17. Tannock I.F., Osoba D., Stockler M.R.et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. a Canadian randomized trial with palliative end points J. Clin. Oncol. 14:1996;1756-1764.
18. Sithisarankul P., Weaver V.M., Diener-West M., Strickland P.T. Multicollinearity may lead to artificial interaction. an example from a cross sectional study of biomarkers Southeast Asian J. Trop. Med. Public Health. 28:1997;404-409.
19. Manual for Clinical Research in Breast Cancer. 3rd edn. 1998;Excerpta Medica, The Netherlands.
20. de Haes J.C.J.M., van Knippenberg F.C.E., Neijt J.P. Measuring psychological and physical distress in cancer patients. structure and application of the Rotterdam Symptom Checklist Br. J. Cancer. 62:1990;1034-1038.
21. Fayers P., Aaronson N., Bjordal K., Curran D., Groenvold M. EORTC QLQ-C30 Scoring Manual. 2nd edn. 1999;EORTC Quality of Life Study Group, Brussels.
22. Pocock S.J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 31:1975;103-115.
23. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
24. Kenneth R.H. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat. Med. 14:1995;1707-1723.
25. Changes and Enhancements 6.11. 1996;SAS Institute Inc, Cary NC, USA.
26. Paridaens R., Biganzoli L., Bruning P.et al. Taxol versus Doxorubicin as first-line single agent chemotherapy for metastatic breast cancer - an EORTC randomized study with crossover. J. Clin. Oncol. 18:2000;724-733.
27. Williams M.R., Todd J.H., Nicholson R.I., Elston C.W., Blamey R.W., Griffiths K. Survival patterns in hormone treated advanced breast cancer. Br. J. Surg. 73:1986;752-755.
28. Robertson J.F.R., Dixon A.R., Nicholson R.I. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. Breast Cancer Research and Treatment. 22:1992;221-227.
29. Blanco G., Holli K., Heikkinen M., Kallioniemi O.P., Taskinen P. Prognostic factors in recurrent breast cancer. relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading Br. J. Cancer. 62:1990;142-146.
30. Herndon J.E., Fleishman S., Kornblith A.B., Kosty M., Green M.R., Holland J. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer. 85:1999;333-340.
31. Ramirez A.J., Towlson K.E., Leaning M.S., Richards M.A., Rubens R.D. Do patients with advanced breast cancer benefit from chemotherapy? Br. J. Cancer. 78:1998;1488-1494.
32. Hauck W.W., Miike R. A proposal for examining and reporting stepwise regressions. Stat. Med. 10:1991;711-715.